The role of P-glycoprotein in drug resistance in multiple myeloma

Leukemia and Lymphoma

Volumn 56, Issue 1, 2015, Pages 26-33

  Abraham, Joseph ^a,b   Salama, Noha N ^b,c   Azab, Abdel Kareem ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ST LOUIS COLLEGE OF PHARMACY   (United States)

^c CAIRO UNIVERSITY   (Egypt)

Author keywords

Chemotherapeutic approaches; Drug resistance; Myeloma

Indexed keywords

ANTINEOPLASTIC AGENT; MULTIDRUG RESISTANCE PROTEIN;

ANIMAL; DRUG RESISTANCE; GENETICS; HUMAN; METABOLISM; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MULTIPLE MYELOMA; NEOPLASMS; P-GLYCOPROTEIN;

EID: 84922380040     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.907890     Document Type: Review

References (93)

1. Anderson KC, Shaughnessy JD, Jr., Barlogie B, Harousseau JL, Roodman GD. Multiple myeloma. Hematology Am Soc Hematol Educ Program 2002:214-240.
2. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-2498.
3. Wang TF, Ahluwalia R, Fiala MA, et al. The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carf lzomib and pomalidomide. Leuk Lymphoma 2013.
4. Hovstadius P, Lindhagen E, Hassan S, et al. Cytotoxic ef ect in vivo and in vitro of CHS 828 on human myeloma cell lines. Anticancer Drugs 2004;15:63-70.
5. McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366:1770-1781.
6. Borrello I. Can we change the disease biology of multiple myeloma? Leuk Res 2012;36 Suppl 1:S3-12.
7. Buda G, Ricci D, Huang CC, et al. Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. Ann Hematol 2010;89:1133-1140.
8. Grogan TM, Spier CM, Salmon SE, et al. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 1993;81:490-495.
9. Kitazono M, Sumizawa T, Takebayashi Y, et al. Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells. J Natl Cancer Inst 1999;91:1647-1653.
10. Pace L, Catalano L, Del Vecchio S, et al. Washout of [99mTc] sestamibi in predicting response to chemotherapy in patients with multiple myeloma. Q J Nucl Med Mol Imaging 2005;49:281-285.
11. Lin B, Catley L, LeBlanc R, et al. Patupilone (epothilone B) inhibits growth and survival of multiple myeloma cells in vitro and in vivo. Blood 2005; 105: 350-357.
12. Schwarzenbach H. Expression of MDR1/P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma. Med Oncol 2002;19:87-104.
13. Mahadevan D. Will MDR-1/P-gp modulators provide clinical benefit in hematologic malignancies? Leuk Res 2006; 30: 1077-1078.
14. Carey SS, Gleason-Guzman M, Gokhale V, Hurley LH. Psorospermin structural requirements for P-glycoprotein resistance reversal. Mol Cancer Ter 2008;7:3617-3623.
15. Jamroziak K, Balcerczak E, Calka K, et al. Polymorphisms and haplotypes in the multidrug resistance 1 gene (MDR1/ABCB1) and risk of multiple myeloma. Leuk Res 2009; 33: 332-335.
16. Wesierska-Gadek J. Major contribution of the multidrug transporter P-glycoprotein to reduced susceptibility of poly(ADP-ribose) polymerase-1 knock-out cells to doxorubicin action. J Cell Biochem 2005;95:1012-1028.
17. Kaye SB, Kerr DJ. Multidrug resistance: clinical relevance in haematological malignancies. Blood Rev 1991; 5: 38-41.
18. Shustik C, Dalton W, Gros P. P-glycoprotein-mediated multidrug resistance in tumor cells: biochemistry, clinical relevance and modulation. Mol Aspects Med 1995;16:1-78.
19. Sonneveld P. Multidrug resistance in haematological malignancies. J Intern Med 2000; 247: 521-534.
20. Vossebeld PJ, Sonneveld P. Reversal of multidrug resistance in hematological malignancies. Blood Rev 1999; 13: 67-78.
21. Hawley TS, Riz I, Yang W, et al. Identif cation of an ABCB1 (P-glycoprotein)-positive carf lzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1. Am J Hematol 2013;88:265-272.
22. Biscardi M, Teodori E, Caporale R, et al. Multidrug reverting activity toward leukemia cells in a group of new verapamil analogues with low cardiovascular activity. Leuk Res 2006;30:1-8.
23. Vangsted A, Klausen TW, Vogel U. Genetic variations in multiple myeloma II: association with ef ect of treatment. Eur J Haematol 2012;88:93-117.
24. Spagnuolo PA, Hu J, Hurren R, et al. The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma. Blood 2010;115:4824-4833.
25. Nakagawa Y, Abe S, Kurata M, et al. IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes. Am J Hematol 2006;81:824-831.
26. Fonti R, Del Vecchio S, Zannetti A, et al. Functional imaging of multidrug resistant phenotype by 99mTc-MIBI scan in patients with multiple myeloma. Cancer Biother Radiopharm 2004;19:165-170.
27. Pilarski LM, Belch AR. Circulating monoclonal B cells expressing P glycoprotein may be a reservoir of multidrug-resistant disease in multiple myeloma. Blood 1994;83:724-736.
28. Salmon SE, Grogan TM, Miller T, Scheper R, Dalton WS. Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining. J Natl Cancer Inst 1989;81:696-701.
29. Aouali N, Eddabra L, Macadre J, Morjani H. Immunosuppressors and reversion of multidrug-resistance. Crit Rev Oncol Hematol 2005;56:61-70.
30. Lehnert M, Dalton WS, Roe D, Emerson S, Salmon SE. Synergistic inhibition by verapamil and quinine of P-glycoprotein-mediated multidrug resistance in a human myeloma cell line model. Blood 1991;77:348-354.
31. Haimovitz-Friedman A, Kan CC, Ehleiter D, et al. Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis. J Exp Med 1994; 180: 525-535.
32. Ford JM. Modulators of multidrug resistance. Preclinical studies. Hematol Oncol Clin North Am 1995;9:337-361.
33. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999; 39: 361-398.
34. Mi Q, Cui B, Silva GL, et al. Pervilleine A, a novel tropane alkaloid that reverses the multidrug-resistance phenotype. Cancer Res 2001;61:4030-4037.
35. Litman T, Druley TE, Stein WD, Bates SE. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical signifcance. Cell Mol Life Sci 2001;58:931-959.
36. List AF, Kopecky KJ, Willman CL, et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 2001; 98: 3212-3220.
37. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58.
38. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in inf uencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000;11:265-283.
39. Krishna R, Mayer LD. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in ef ective therapy of multidrug resistant solid tumors. Cancer Res 1997; 57: 5246-5253.
40. Krishna R, McIntosh N, Riggs KW, Mayer LD. Doxorubicin encapsulated in sterically stabilized liposomes exhibits renal and biliary clearance properties that are independent of valspodar (PSC 833) under conditions that signif cantly inhibit nonencapsulated drug excretion. Clin Cancer Res 1999;5:2939-2947.
41. Krishna R, St.-Louis M, Mayer LD. Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by coadministering valspodar (PSC 833) with sterically stabilized liposomal doxorubicin. 2000. 131-141 p.
42. Krishna R, Mayer LD. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in ef ective therapy of multidrug-resistant solid tumors. Cancer Res 1997; 57: 5246-5253.
43. Krishna R, St-Louis M, Mayer LD. Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by co-administering valspodar (PSC 833) with sterically stabilized liposomal doxorubicin. Int J Cancer 2000;85:131-141.
44. Krishna R, McIntosh N, Riggs KW, Mayer LD. Doxorubicin encapsulated in sterically stabilized liposomes exhibits renal and biliary clearance properties that are independent of valspodar (PSC 833) under conditions that signif cantly inhibit nonencapsulated drug excretion. Clin Cancer Res 1999;5:2939-2947.
45. Mechetner EB, Roninson IB. Ef cient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody. Proc Natl Acad Sci U S A 1992;89:5824-5828.
46. Pennock GD, Dalton WS, Roeske WR, et al. Systemic toxic ef ects associated with high-dose verapamil infusion and chemotherapy administration. J Natl Cancer Inst 1991;83:105-110.
47. Bohme M, Buchler M, Muller M, Keppler D. Dif erential inhibition by cyclosporins of primary-active ATP-dependent transporters in the hepatocyte canalicular membrane. FEBS Lett 1993; 333: 193-196.
48. Lum BL, Gosland MP. MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors. Hematol Oncol Clin North Am 1995;9:319-336.
49. Bartlett NL, Lum BL, Fisher GA, et al. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 1994;12:835-842.
50. Giaccone G, Linn SC, Welink J, et al. A dose-f nding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors. Clin Cancer Res 1997;3:2005-2015.
51. Boote DJ, Dennis IF, Twentyman PR, et al. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 1996;14:610-618.
52. Sarris AH, Younes A, McLaughlin P, et al. Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1996;14:233-239.
53. Erlichman C, Moore M, Thiessen J, DeAngelis C, Goodman P, Manzo J. A phase I trial of doxorubicin (DOX) and PSC 833, a modulator of multidrug resistance (MDR): 97. Anticancer Drugs 1994;5:42.
54. Watts GS, Futscher BW, Isett R, Gleason-Guzman M, Kunkel MW, Salmon SE. cDNA microarray analysis of multidrug resistance: doxorubicin selection produces multiple defects in apoptosis signaling pathways. J Pharmacol Exp Ter 2001;299:434-441.
55. Kolesnick RN, Kronke M. Regulation of ceramide production and apoptosis. Annu Rev Physiol 1998;60:643-665.
56. Amiri-Kordestani L, Basseville A, Kurdziel K, Fojo AT, Bates SE. Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies. Drug Resist Updat 2012; 15: 50-61.
57. Xu YC, Lin YM, Zhang FC. [T e relationship between abnormal MDR gene expression and chemotherapy response in lymphoid malignancies]. Zhonghua Zhong Liu Za Zhi 2006; 28: 353-356.
58. Yeh JJ, Hsu WH, Wang JJ, Ho ST, Kao A. Predicting chemotherapy response to paclitaxel-based therapy in advanced non-small-cell lung cancer with P-glycoprotein expression. Respiration 2003;70:32-35.
59. Chaudhary PM, Roninson IB. Induction of multidrug resistance in human cells by transient exposure to dif erent chemotherapeutic drugs. J Natl Cancer Inst 1993;85:632-639.
60. Juranka PF, Zastawny RL, Ling V. P-glycoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins. FASEB J 1989;3:2583-2592.
61. Ao L, Wu Y, Kim D, et al. Development of Peptide-Based Reversing Agents for P-Glycoprotein-Mediated Resistance to Carflzomib. Mol Pharm 2012.
62. Verbrugge SE, Assaraf YG, Dijkmans BA, et al. Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo ef cacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis. J Pharmacol Exp Ter 2012;341:174-182.
63. Rumpold H, Salvador C, Wolf AM, Tilg H, Gastl G, Wolf D. Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors. Biochem Biophys Res Commun 2007; 361: 549-554.
64. Michaelis M, Fichtner I, Behrens D, et al. Anti-cancer ef ects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo. Int J Oncol 2006; 28: 439-446.
65. O'Connor R, Ooi MG, Meiller J, et al. The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias. Cancer Chemother Pharmacol 2013;71:1357-1368.
66. Dalton WS, Grogan TM, Meltzer PS, et al. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 1989; 7: 415-424.
67. Obaidat A, Weiss J, Wahlgren B, et al. Proteasome regulator marizomib (NPI-0052) exhibits prolonged inhibition, attenuated ef ux, and greater cytotoxicity than its reversible analogs. J Pharmacol Exp Ter 2011;337:479-486.
68. Iijima M, Momose I, Ikeda D. Increased ABCB1 expression in TP-110-resistant RPMI-8226 cells. Biosci Biotechnol Biochem 2010;74:1913-1919.
69. Allegra A, Alonci A, Gerace D, et al. New orally active proteasome inhibitors in multiple myeloma. Leuk Res 2013.
70. Mateos MV, Ocio EM, San Miguel JF. Novel generation of agents with proven clinical activity in multiple myeloma. Semin Oncol 2013;40:618-633.
71. Roovers DJ, van Vliet M, Bloem AC, Lokhorst HM. Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines. Leuk Res 1999; 23: 539-548.
72. Bellamy W T, Dalton WS, Kailey JM, et al. Verapamil reversal of doxorubicin resistance in multidrug-resistant human myeloma cells and association with drug accumulation and DNA damage. Cancer Res 1988;48:6365-6370.
73. Tsubaki M, Satou T, Itoh T, et al. Overexpression of MDR1 and survivin, and decreased Bim expression mediate multidrug-resistance in multiple myeloma cells. Leuk Res 2012; 36: 1315-1322.
74. Yang HH, Ma MH, Vescio RA, Berenson JR. Overcoming drug resistance in multiple myeloma: the emergence of therapeutic approaches to induce apoptosis. J Clin Oncol 2003;21:4239-4247.
75. Sonneveld P, Suciu S, Weijermans P, et al. CyclosporinA combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914). Br J Haematol 2001;115:895-902.
76. Mongkonsritragoon W, Kimlinger T, Ahmann G, Greipp PR. Is multidrug resistance (P-glycoprotein) an intrinsic characteristic of plasma cells in patients with monoclonal gammopathy of undetermined signif cance, plasmacytoma, multiple myeloma and amyloidosis? Leuk Lymphoma 1998;29:577-584.
77. Salmon SE, Dalton WS, Grogan TM, et al. Multidrug-resistant myeloma: laboratory and clinical ef ects of verapamil as a chemosensitizer. Blood 1991;78:44-50.
78. Kuhne A, Tzvetkov MV, Hagos Y, Lage H, Burckhardt G, Brockmoller J. Inf ux and ef ux transport as determinants of melphalan cytotoxicity: Resistance to melphalan in MDR1 overexpressing tumor cell lines. Biochem Pharmacol 2009; 78: 45-53.
79. Kofa G, Turner V, Schulz B, et al. Doxorubicin induces drug ef ux pumps in Candida albicans. Med Mycol 2011;49:132-142.
80. Zhang J, Tian Q, Chan SY, Duan W, Zhou S. Insights into oxazaphosphorine resistance and possible approaches to its circumvention. Drug Resist Updat 2005;8:271-297.
81. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P. A bsence of the mdr1a P-Glycoprotein in mice af ects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 1995;96:1698-1705.
82. Ishikawa H, Tanaka H, Iwato K, et al. Ef ect of glucocorticoids on the biologic activities of myeloma cells: inhibition of interleukin-1 beta osteoclast activating factor-induced bone resorption. Blood 1990;75:715-720.
83. Rajkumar SV, Witzig TE. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Cancer Treat Rev 2000; 26: 351-362.
84. Zhu YX, Braggio E, Shi CX, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011;118:4771-4779.
85. Trussardi-Regnier A, Lavenus S, Gorisse MC, Dufer J. T alidomide alters nuclear architecture without ABCB1 gene modulation in drug-resistant myeloma cells. Int J Oncol 2009;35:641-647.
86. Hus M, Dmoszynska A, Kocki J, et al. Long-term thalidomide therapy resulted in lack of mdr1 gene expression in a patient with primary resistant multiple myeloma. Leukemia 2005;19:1497-1499.
87. Beghin D, Delongeas JL, Claude N, Farinotti R, Forestier F, Gil S. Comparative ef ects of drugs on P-glycoprotein expression and activity using rat and human trophoblast models. Toxicol In Vitro 2010; 24: 630-637.
88. van de Donk NW, Gorgun G, Groen RW, et al. Lenalidomide for the treatment of relapsed and refractory multiple myeloma. Cancer Manag Res 2012;4:253-268.
89. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133-2142.
90. Hofmeister CC, Yang X, Pichiorri F, et al. Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein. J Clin Oncol 2011;29:3427-3434.
91. Takahashi N, Miura M, Kameoka Y, Abumiya M, Sawada K. Drug interaction between lenalidomide and itraconazole. Am J Hematol 2012;87:338-339.
92. Chanan-Khan AA, Swaika A, Paulus A, et al. Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. Blood Cancer J 2013;3:e143.
93. Gay F, Mina R, Troia R, Bringhen S. Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma. Expert Opin Drug Metab Toxicol 2013;9:1517-1527.